The rationale behind Lilly's $1.1 billion takeover of Dermira

11 February 2020

Eli Lilly (NYSE: LLY) is to spend more than $1 billion on the takeover of dermatology specialist Dermira.

Why is the US drugmaker so keen to add to its pipeline and what was it about this company that appealed?

The purchase of Dermira will enable Lilly to boost its immunology pipeline, with the addition of the atopic dermatitis biologic lebrikizumab and Qbrexa (glycopyrronium) for the topical treatment of primary axillary hyperhidrosis (excessive sweating).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK